Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
INSP gained roughly 30% over the 21 trading days ending September 14. Inspire V is now used by more than three-quarters of implanting centers, EPS guidance was raised, and favorable physician adoption and 2026 reimbursement trends support continued momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Position ⢠Margin Compression ⢠High Stock Compensation INSP's strong liquidity, low leverage, and positive free cash flow are offset by near-breakeven quarterly profitability, heavy stock-based compensation, and deteriorating margins, warranting caution until costs stabilize.
Price Behavior
Key Price Behavior Insights: ⢠Strong upward momentum ⢠New high breakout ⢠Pullback risk Support Level: $68.12; $62.00â$63.00 Resistance Level: $73.00 INSP surged ~25% over the last month to a new high of $73.00, but its overbought RSI signals pullback risk toward $68.12 support.
Sentiment & News
Key News Insights: ⢠Inspire V Adoption ⢠Reimbursement Risks ⢠Mixed Institutions INSP's growth outlook is supported by Inspire V adoption and easing reimbursement pressure, but reimbursement, valuation, and profitability risks warrant caution.
AI Summary
INSP is a recovery-and-execution investment, with upside dependent on Medicare reimbursement normalization translating into demonstrable implant-volume and margin recovery by 2027ânot merely policy progressâwhile Inspire V delays and a stock already pricing in improvement elevate downside risk.
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 14 | Sep 21 | INSP | Inspire Medical Systems, Inc. | INSP gained roughly 30% over the 21 trading days ending September 14. Inspire V is now used by more than three-quarters of implanting centers, EPS guidance was raised, and favorable physician adoption and 2026 reimbursement trends support continued momentum. | Active | +0.0% |
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |